Atrium Health Levine Cancer Institute | Strategic Alliance Partners

July 07, 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.

July 01, 2021

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

June 21, 2021

June 02, 2021

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

May 20, 2021

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

May 18, 2021

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

May 10, 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

April 30, 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

April 27, 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

April 26, 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

April 23, 2021

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

April 22, 2021

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

April 20, 2021

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

April 20, 2021

Saad Z. Usmani, MD, FACP, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

April 16, 2021

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

April 16, 2021

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

April 15, 2021

Saad Z. Usmani, MD, FACP, discusses the rapidly changing cellular therapy paradigm in relapsed/refractory multiple myeloma.

April 05, 2021

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

March 25, 2021

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.

March 09, 2021

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

March 09, 2021

March 01, 2021

February 23, 2021

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

February 22, 2021

Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma.

January 27, 2021

During the question-and-answer portion of the virtual Institutional Perspectives in Cancer webinar, Earle Burgess, MD, and colleagues provide insight into how they are navigating the evolving treatment landscape of renal cell carcinoma and bladder cancer.

January 21, 2021

Justin T. Matulay, MD, discusses whether there is a role for cytoreductive nephrectomy in metastatic renal cell carcinoma, as well as key data that have helped guide this paradigm.

January 11, 2021

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

January 08, 2021

Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.

January 08, 2021

Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.

December 29, 2020

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.